急性肺损伤/急性呼吸窘迫综合征幸存者新冠后急性期后遗症持续超过3年,但与持续性血栓炎症或内皮功能障碍无关
该单中心前瞻性队列纳入150例第一波疫情中重症及危重症新冠成年幸存者,采样加权使50%为机械通气幸存者。在出院时、4个月、15个月和3年检测11种血清生物标志物,15个月和3年评估症状和躯体功能,PASC采用RECOVER定义(12种症状及评分)。15个月和3年时均有26%的参与者存在PASC,PASC及症状表型一致与更高的衰弱表型类别、更差的简易体能状况量表评分和更短的6分钟步行距离相关。包括白细胞介素-6、可溶性肿瘤坏死因子受体-1、血管生成素、C2、C4b和C5在内的炎症、内皮功能和补体生物标志物在横断面或纵向分析中均与PASC或症状表型无关。
要点
- 重症及危重症新冠ALI/ARDS幸存者中,15个月和3年时PASC患病率均为26%。
- PASC及劳累后不适、疲劳、脑雾症状表型在15个月和3年时一致与更高衰弱表型类别、更差简易体能状况量表评分和更短6分钟步行距离相关。
- 白细胞介素-6、可溶性肿瘤坏死因子受体-1、血管生成素、C2、C4b和C5在横断面或纵向分析中均与PASC或症状表型无关。
- 该队列为单中心前瞻性设计,150例成年幸存者,平均年龄56岁(标准差13),67%为西班牙裔,25%为黑人。
- 作者认为未来研究应采用多组学阐明PASC的潜在机制。
适用人群与场景
- 第一波疫情期间重症及危重症新冠成年幸存者,单中心前瞻性队列,采样加权使50%为机械通气幸存者。
诊断标准与关键阈值
- PASC采用Researching COVID to Enhance Recovery(RECOVER)定义,基于12种症状及评分判定。
研究设计与关键结果
- 单中心前瞻性队列,150例成年幸存者,平均年龄56岁(标准差13),67%为西班牙裔,25%为黑人。
- 15个月和3年时PASC患病率均为26%。
- PASC及劳累后不适、疲劳、脑雾症状表型在15个月和3年时一致与更高衰弱表型类别、更差简易体能状况量表评分和更短6分钟步行距离相关。
- 白细胞介素-6、可溶性肿瘤坏死因子受体-1、血管生成素、C2、C4b和C5在横断面或纵向分析中均与PASC或症状表型无关。
证据类型、等级与局限
- 证据类型:单中心前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为未来研究应采用多组学阐明PASC的潜在机制。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Inflammation, endothelial dysfunction, and complement activation are associated with COVID-19 acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).
OBJECTIVES: We hypothesized that higher levels of inflammation, endothelial dysfunction, and complement activation implicated in more severe COVID-19 ALI/ARDS are associated with post-acute sequelae of COVID-19 (PASC) phenotypes in the 3 years after hospitalization.
DESIGN, SETTING, AND PARTICIPANTS: A single-center prospective cohort of 150 adult survivors of severe and critical COVID-19 from the first wave of the pandemic with sampling weighted to include 50% survivors of mechanical ventilation.
MAIN OUTCOMES AND MEASURES: Eleven serum biomarkers at hospital discharge, 4 months, 15 months, and 3 years, and symptoms and physical function at 15 months and 3 years. PASC presence was defined using the 12 symptoms and scoring from the Researching COVID to Enhance Recovery (RECOVER) definition. We tested associations of biomarkers with PASC and symptom phenotypes of post-exertional malaise, fatigue, and brain fog while adjusting for age, sex, body mass index, comorbidities, and days since COVID-19 diagnosis.
RESULTS: The mean (sd) age of the cohort was 56 years (13); 67% were Hispanic and 25% were Black. PASC was present in 26% of participants at both 15 months and 3 years. PASC and symptom phenotypes at 15 months and 3 years were consistently associated with higher frailty phenotype category, worse short physical performance battery scores, and shorter 6-minute walk distance. Biomarkers of inflammation, including interleukin-6 and soluble tumor necrosis factor receptor-1, endothelial function, including angiopoietin, and complement, including C2, C4b, and C5, were not associated with PASC or symptom phenotypes in cross-sectional or longitudinal analyses.
CONCLUSIONS AND RELEVANCE: PASC persists for 3 years after acute COVID-19 ALI/ARDS, is associated with frailty, but not associated with persistently higher levels of inflammatory, endothelial, and complement biomarkers implicated in worse short-term outcomes in acute COVID-19, non-COVID-19 ARDS, and sepsis. Future studies should employ multiomics to elucidate potential mechanisms of PASC.
参考来源
- Jones AE, Khan Z, McGroder CF, et al. Post-Acute Sequelae of COVID-19 Persist Over 3 Years in Acute Lung Injury/Acute Respiratory Distress Syndrome Survivors But Are Not Associated With Persistent Thromboinflammation or Endothelial Dysfunction. Crit Care Explor. 2026. PMID: 41824803. doi:10.1097/CCE.0000000000001390
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。